Regeneron Pharmaceuticals Inc
Symbol: REGN (NASDAQ)
568.53
▲ (2.28%) 12.700
Company Description:
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Key Stats
- Today's Open: $555.81
- Today's High: $570.855
- Today's Low: $555.751
- Today's Volume: 868.38K
- Yesterday Close: $555.83
- Yesterday High: $560
- Yesterday Low: $552.98
- Yesterday Volume: 874.73K
- Last Min Volume: 4
- Last Min High: $568.53
- Last Min Low: $568.53
- Last Min VWAP: $568.53
Company Profile
- Name: Regeneron Pharmaceuticals Inc
- Website: https://www.regeneron.com
- Listed Date: 1991-04-02
- Location: TARRYTOWN, NY
- Market Status: Active
- CIK Number: 0000872589
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $58.91B
- Round Lot: 100
- Outstanding Shares: 105.99M
- Asset Type: CS
RECENT FILINGS FOR REGN
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-06 | SCHEDULE 13G/A | View |
| 2025-08-01 | 13F-HR | View |
| 2025-08-01 | 10-Q | View |
| 2025-08-01 | 8-K | View |
| 2025-06-18 | 8-K | View |
| 2025-06-05 | SCHEDULE 13G/A | View |
| 2025-05-02 | 13F-HR | View |
| 2025-04-29 | 10-Q | View |
| 2025-04-29 | 8-K | View |
| 2025-04-29 | ARS | View |
| 2025-04-29 | DEFA14A | View |
| 2025-04-29 | DEF 14A | View |
| 2025-04-22 | SCHEDULE 13G/A | View |
| 2025-04-17 | UPLOAD | View |
| 2025-04-07 | PRE 14A | View |
| 2025-04-03 | CORRESP | View |
| 2025-03-21 | UPLOAD | View |
| 2025-02-12 | SCHEDULE 13G/A | View |
| 2025-02-07 | 13F-HR | View |
| 2025-02-05 | 10-K | View |
Latest News on REGN